Hoopmann, M., Sachse, K., Valter, M. M., Becker, M., Neumann, R., Ortmann, M., Goehring, U. -J., Thomas, A., Mallmann, P. and Schoendorf, T. (2010). Serological and immunohistochemical HER-2/neu statuses do not correlate and lack prognostic value for ovarian cancer patients. Eur. J. Cancer Care, 19 (6). S. 809 - 816. HOBOKEN: WILEY. ISSN 1365-2354

Full text not available from this repository.

Abstract

The serodiagnostics of extracellular domain (ECD) HER-2/neu has turned into an evidenced-based tumour marker for HER-2/neu-positive breast cancer patients. This study investigated the clinical relevance of immunohistochemical and serum HER-2/neu in 44 patients with advanced ovarian cancer. The Hercept-Test (R) from DAKO Diagnostics was used to analyse immunohistochemical HER-2/neu expression. The HER-2/neu ECD in serum was determined quantitatively by Bayer Immuno 1 (TM) Immunoanalyser. The HER-2/neu serum values were correlated to the clinical course of disease and to established prognostic factors, i.e. progression-free and overall survival. Some 23% of patients (n = 11) expressed HER-2/neu serum levels higher than 15 ng/mL, whereas only 7.7% (n = 2) of the patients examined by immunohistochemistry showed a HER-2/neu overexpression of the tissue. None of them revealed an overexpression of HER-2/neu ECD by serodiagnostics. HER-2/neu overexpression did not correlate significantly to any of the analysed prognostic factors. According to progression-free and overall survival, there was no significant difference between serologically HER-2/neu-positive or negative patients. For ovarian cancer patients, neither high HER-2/neu serum levels, nor immunohistochemically determined HER-2/neu positivity, appear to predict the course of disease. This study shows a lack of association between the immunohistochemical HER-2/neu status and the serum level of solute extracelluar HER-2/neu domain.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Hoopmann, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sachse, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Valter, M. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Becker, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Neumann, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ortmann, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goehring, U. -J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thomas, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mallmann, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schoendorf, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-493246
DOI: 10.1111/j.1365-2354.2009.01112.x
Journal or Publication Title: Eur. J. Cancer Care
Volume: 19
Number: 6
Page Range: S. 809 - 816
Date: 2010
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1365-2354
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
METASTATIC BREAST-CANCER; ONCOGENE C-ERBB-2 HER2/NEU; IN-SITU HYBRIDIZATION; CLINICAL UTILITY; PREDICTIVE-VALUE; NEU ONCOGENE; SERUM; OVEREXPRESSION; CARCINOMA; TRASTUZUMABMultiple languages
Oncology; Health Care Sciences & Services; Nursing; RehabilitationMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/49324

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item